Giant Cell Arteritis - FOI Response Register

1.    Does your trust or health board treat giant cell arteritis (GCA)? If not, please provide the name of the hospital or trust that you refer GCA patients to.

Yes

2.    In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were:

Admitted as an inpatient

<5 (see below)

Treated in A&E

<5 (see below)

3.    How many patients were treated by the rheumatology department in the past 3 months with the following:

Tocilizumab – for any disease  

<5 (see below)

Tocilizumab for rheumatoid arthritis (RA) only  

<5 (see below)

Tocilizumab for giant cell arteritis (GCA) only

In accordance with FOISA s 17(1), NHS Shetland confirms that it does not hold the information requested. 

4.    How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?

0

5.    How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab?

0

Where we have given <5 answers this is because providing more specific detail carries a high risk of identifying individuals. As such, and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.